Cellular immunotherapy for ovarian cancer

Expert Opinion on Biological Therapy

Volumn 9, Issue 6, 2009, Pages 677-688

  Cannon, Martin J ^a   O'Brien, Timothy J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

CD4+ T cells; Dendritic cells; Interleukin 1 ; Interleukin 15; Interleukin 2; Ovarian cancer; Regulatory T cells; Th17 T cells

Indexed keywords

CANCER VACCINE; CD137 ANTIGEN; CD28 ANTIGEN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUDARABINE; FOLATE RECEPTOR; FOLATE RECEPTOR ALPHA; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMATINIB; INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; LYMPHOCYTE RECEPTOR; MESOTHELIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MUCIN 1; NATURAL KILLER CELL RECEPTOR NKG2D; NY ESO 1 ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; STROMAL CELL DERIVED FACTOR 1; T LYMPHOCYTE RECEPTOR ZETA CHAIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC FINGER PROTEIN;

ABSENCE OF SIDE EFFECTS; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; BREAST TUMOR; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOMA; CD4+ T LYMPHOCYTE; CELL MATURATION; CELL THERAPY; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMMUNITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MELANOMA; MESOTHELIOMA; METASTASIS; MYELOMA; NONHUMAN; OVARY CANCER; RECURRENT CANCER; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

ADOPTIVE TRANSFER; FEMALE; HUMANS; OVARIAN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 67649118309     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902932897     Document Type: Review

References (121)

1. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167-181
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
3. Schlienger K, Chu CS, Woo EY, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003;9:1517-1527 (Pubitemid 36418410)
4. Santin AD, Hermonat PL, Ravaggi A, et al. Induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells in patients with advanced ovarian cancer. Am J Obstet Gynecol 2000;183:601-609
5. Santin AD, Bellone S, Ravaggi A, et al. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 2000;96:422-430 (Pubitemid 30674287)
6. Zhao X, Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest 2001;30:33-45 (Pubitemid 32587693)
7. Gong J, Nikrui N, Chen D, et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000;165:1705-1711 (Pubitemid 30604610)
8. Chiang CL-L, Ledermann JA, Rad AN, et al. Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunol Immunother 2006;55:1384-1395 (Pubitemid 44187670)
9. Hernando JJ, Park T-W, Kubler K, et al. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51:45-52 (Pubitemid 34158522)
10. Hernando JJ, Park T-W, Fischer H-P, et al. Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-α for relapsed metastatic ovarian cancer. Lancet Oncol 2007;8:451-454 • This case report illustrates the clinical potential of DC vaccination for ovarian cancer, showing durable clinical responses up to 16 months after treatment. (Pubitemid 46621775)
11. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-2632 (Pubitemid 34575634)
12. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002;23:154-169 • Most probably the definitive report on the sequence and protein backbone of CA125. (Pubitemid 44858307)
13. Bellone S, Anfossi S, O'Brien TJ, et al. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen A2-positive healthy donors and patients with advanced ovarian cancer. Am J Obstet Gynecol 2009;200:75.e1-10
14. Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol 2004;16:87-92 (Pubitemid 38241547)
15. Tanimoto H, Underwood LJ, Shigemasa K, et al. The stratum corneum chymotryptic enzyme which mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999;86:2074-2082
16. Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998;160:3363-3373 (Pubitemid 28164729)
17. Bondurant KL, Crew MD, Santin AD, et al. Definition of an immunodominant region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Clin Cancer Res 2005;11:3446-3454 • Identification of a multi-epitope domain within stratum corneum chymotryptic enzyme, allowing DC-driven stimulation of CD4+ T cell responses from individuals of diverse HLA type, and cross-priming of CD8+ CTL responses. (Pubitemid 40627899)
18. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;343:203-213 (Pubitemid 36077915)
19. Fujita K, Ikarishi H, Takakuwa K, et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res 1995;1:501-507
20. Freedman RS, Platsoucas CD. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treat Res 1996;82:115-146
21. Santin AD, Bellone S, Palmieri M, et al. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. Int J Gynecol Cancer 2004;14:64-75 (Pubitemid 38280625)
22. Barber A, Zhang T, DeMars LR, et al. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 2007;67:5003-5008 (Pubitemid 46910210)
23. Carpenito C, Milone M, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009;106:3360-3365
24. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-6115 (Pubitemid 44703776)
25. Baxevanis CN, Voutsas IF, Tsitsilonis OE, et al. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000;164:3902-3912 (Pubitemid 30169850)
26. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity. Cancer Immunol Immunother 2005;54:721-728
27. Hwang M, Lukens JR, Bullock TNJ. Cognate memory CD4+ T cells generated with dendritic cell priming influnce the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control. J Immunol 2007;179:5829-5838
28. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008;222:129-144
29. Perez-Diez A, Joncker NT, Choi K, et al. CD4 T cells can be more efficient at tumor rejection than CD8 T cells. Blood 2007;109:5346-5354 •• This paper underlines the potential value of CD4+ T cell responses in antitumor immunity, suggesting that CD4+ T cells may be more effective than CD8+ T cells even when tumors lack MHC class II expression. (Pubitemid 46890556)
30. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-2703 •• An important clinical study showing that adoptive transfer of tumor antigen-specific autologous CD4+ T cells can be a highly effective strategy for immunotherapy. (Pubitemid 351860862)
31. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 2007;104:12837-12842 (Pubitemid 47255241)
32. Matsuzaki J, Qian F, Luescher I, et al. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother 2008;57:1185-1195
33. Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesis of the gonad after neonatal thymectomy in mice. Science 1969;166:753-755
34. Nishizuka Y, Sakakura T, Taguchi O. Mechanism of ovarian tumorigenesis in mice after neonatal thymectomy. Natl Cancer Inst Monogr 1979;51:89-96 (Pubitemid 9239331)
35. Samy ET, Wheeler KM, Roper RJ, et al. Autoimmune disease in day 3 thymectomized mice is actively controlled by endogenous disease-specific regulatory T cells. J Immunol 2008;180:4366-4370
36. Smith H, Chen IM, Kubo R, Tung KS. Neonatal thymectomy results in a repertoire enriched in T cells deleted in adult thymus. Science 1989;245:749-752 (Pubitemid 19214009)
37. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian cancer fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949 •• A landmark study showing that Treg infiltration of ovarian tumors correlates inversely with a poor prognosis and increased mortality. (Pubitemid 39273735)
38. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11:8326-8331 • Further evidence of a probable role for Treg in ovarian cancer pathogenesis, in this case shown by the inverse correlation of foxp3 expression with reduced overall survival. (Pubitemid 41746944)
39. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800 (Pubitemid 34887242)
40. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7 • Blockade of B7-H1 enhanced DC-mediated T cell activation and boosted the efficacy of adoptive T cell immunotherapy, providing experimental evidence that B7-H1 suppresses antitumor immunity. (Pubitemid 36597102)
41. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-477 (Pubitemid 351733418)
42. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104:3360-5 • Important clinical evidence that high B7-H1 (PD-L1) expression by ovarian tumors correlates with a poor prognosis, compared with those patients with tumors that expressed low levels of B7-H1. (Pubitemid 46364164)
43. Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian cancer. J Exp Med 2006;203:871-881
44. Simon I, Zhuo S, Corrai L, et al. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 2006;66:1570-1575 (Pubitemid 43259939)
45. Tringler B, Liu W, Corrai L, et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol 2006;100:44-52 (Pubitemid 41815048)
46. Kryczek I, Wei S, Zou L, et al. Induction of B7-H4 on APCs through Il-10: novel suppressive mode for regulatory T cells. J Immunol 2006;177:40-44 (Pubitemid 43939113)
47. Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007;67:8900-8905 • Clinical analysis of ovarian cancer patients, showing that B7-H4 expression by tumor-associated macrophages correlated with a poor prognosis. (Pubitemid 47437467)
48. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-1346 (Pubitemid 34007939)
49. Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005;65:5020-5026 (Pubitemid 40827308)
50. Huarte E, Cubillos-Ruiz JR, Nesbeth YC, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008;68:7684-7691
51. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006;107:628-636 (Pubitemid 43076387)
52. Banerjee DK, Dhodapkar MV, Matayeva E, et al. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006;108:2655-2661 • A brief but notable study, showing that cytokine maturation of DC does not prevent activation and expansion of foxp3+ Treg following administration to myeloma patients. (Pubitemid 44777001)
53. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-1222 (Pubitemid 30826423)
54. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238 (Pubitemid 32524454)
55. Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 1980;151:69-80 (Pubitemid 10168540)
56. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982;155:1063-1074
57. Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 1989;49:1649-1654 •• With reference 56, landmark studies showing that cyclophosphamide treatment enhanced antitumor immunotherapy by elimination of CD4+ suppressor T cells (Treg). (Pubitemid 19108381)
58. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-344 (Pubitemid 39255944)
59. Loeffler M, Kruger JA, Reisfeld RA. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 2005;65:5027-5030 (Pubitemid 40827309)
60. Ikezawa Y, Nakazawa M, Tamura C, et al. Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. Dermatol Sci 2005;39:105-112 (Pubitemid 41073976)
61. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4+CD25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-2868 (Pubitemid 40446280)
62. Nor JE, Mitra RS, Sutorik MM, et al. Thrombospondin-1 induces endothelial cells apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 2000;37:209-218 (Pubitemid 30350890)
63. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003;100:12917-12922 (Pubitemid 37340000)
64. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004;36:1038-1045 (Pubitemid 38501556)
65. Grimbert P, Bouguermouh S, Baba N, et al. Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation. J Immunol 2006;177:3534-3541 (Pubitemid 44359884)
66. Shimizu J, Yamazuki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-5218
67. Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and Interleukin-2. J Immunother 2005;28:120-128
68. Imai H, Saio M, Nonaka K, et al. Depletion of CD4+CD25+ regulatory T cells enhances interelukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 2007;98:416-423 (Pubitemid 46195615)
69. Knutson KL, Dang Y, Lu H, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 2006;177:84-91 (Pubitemid 43939119)
70. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-3633 • This paper provides clinical evidence that treatment with ONTAK (denileukin diftitox) can deplete Treg in peripheral blood and enhances immunological and clinical responses to DC vaccination. (Pubitemid 43121851)
71. Attia P, Maker AV, Haworth LR, et al. Inability of fusion protein of IL-2 and diphtheria toxin (Denileukin diftitix, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005;28:582-592 (Pubitemid 41533092)
72. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-1174 (Pubitemid 46718401)
73. Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go? Nat Clin Pract Oncol 2006;3:668-681
74. Thistlethwaite FC, Elkord E, Griffiths RW, et al. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother 2008;57:623-634 (Pubitemid 351641025)
75. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018-2025 (Pubitemid 41291715)
76. Hegde U, Chhabra A, Chattopadhyay S, et al. Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes. Pathobiology 2008;75:200-208
77. Larmonier N, Janikashvili N, LaCasse CJ, et al. Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol 2008;181:6955-6963 • An interesting report that Gleevec inhibits Treg function and enhances antitumor responses following DC vaccination, suggesting that Gleevec may have clinical value as an adjuvant for cellular immunotherapy.
78. Yamazaki S, Iyoda T, Tarbell K, et al. Direct expansion of functional CD25+CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003;198:235-247 (Pubitemid 37009740)
79. Jarnicki AG, Conroy H, Brereton C, et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008;180:3797-3806 •• A significant paper, showing a direct link between p38 MAPK activity in DC and the capacity of DC to induce Treg activity: p38 MAPK inhibition diminished Treg infiltration of tumors and enhanced the efficacy of DC immunotherapy.
80. Wang S, Hong S, Yang J, et al. Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006;108:4071-4077 (Pubitemid 44913277)
81. Adler HS, Kubsch S, Graulich E, et al. Activation of MAP kinase p38 is critical for the cell-cycle-controlled suppressor function of regulatory T cells. Blood 2007;109:4351-4359 (Pubitemid 46743403)
82. Xu S, Koski GK, Faries M, et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003;171:2251-2261 (Pubitemid 37025530)
83. Maillard RB, Wankowicz-Kalinska A, Cai Q, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004;64:5934-5937 (Pubitemid 39129387)
84. ten Brinke A, Karsten ML, Dieker MC, et al. The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine 2007;25:7145-7152
85. Muthuswamy R, Urban J, Lee J-J, et al. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 2008;68:5972-5978
86. Song XT, Evel-Kabler K, Shen L, et al. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med 2008;14:258-265 (Pubitemid 351347913)
87. Breckpot K, Aerts-Toegaert C, Heirman C, et al. Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J Immunol 2009;182:860-870
88. + T cells to Treg.
89. Waldmann TA. Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arth Res Ther 2004;6:174-177 (Pubitemid 39162380)
90. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+CD25hiFoxp3+ regulatory T cells in cancer patients. Blood 2006;107:2409-2414
91. Wei S, Kryczek I, Edwards RP, et al. Interleukin-2 administration alters the CD4+Foxp3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007;67:7487-7494 • Clinical study showing that IL-2 administration results in Treg expansion (see also reference 90). (Pubitemid 47206578)
92. Antony PA, Paulos CM, Ahmadzadeh M, et al. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol 2006;176:5255-5266
93. Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004;101:1969-1974 (Pubitemid 38228999)
94. Rubinstein MP, Kadima AN, Salem ML, et al. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J Immunol 2002;169:4928-4935 (Pubitemid 35217158)
95. Teague RM, Sather BD, Sacks JA, et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006;12:335-341 • A strong illustration of the potential of IL-15 as an adjuvant for cellular immunotherapy against cancer, through its ability to break T cell tolerance to self antigens. (Pubitemid 43355083)
96. Dubois SP, Waldmann TA, Muller JR. Survival adjustment of mature dendritic cells by IL-15. Proc Natl Acad Sci USA 2005;102:8662-8667 (Pubitemid 40862792)
97. Mohamadzadeh M, Berard F, Essert G, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 2001;194:1013-1019 (Pubitemid 32953269)
98. Pulendran B, Dillon S, Joseph C, et al. Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur J Immunol 2004;34:66-73 • This paper shows that IL-15 can modify DC function, enhancing DC-driven CD8+ CTL responses. (Pubitemid 38111521)
99. Jordan MS, Boesteanu A, Reed AJ, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self peptide. Nat Immunol 2001;2:301-306 (Pubitemid 33706340)
100. Romagnoli P, Hudrisier D, van Meerwijk JPM. Preferential recognition of self antigens despite normal thymic deletion of CD4+CD25+ regulatory T cells. J Immunol 2002;168:1644-1648 (Pubitemid 34135759)
101. Romagnoli P, Hudrisier D, van Meerwijk JPM. Molecular signature of recent thymic selection events on effector and regulatory CD4+ T lymphocytes. J Immunol 2005;175:5751-5758 (Pubitemid 41508058)
102. Hsieh CS, Liang Y, Tyznik AJ, et al. Recognition of the peripheral self by naturally arising CD25+CD4+ T cell receptors. Immunity 2004;21:267-277
103. Cozzo C, Larkin III J, Caton AJ. Self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 2003;171:5678-5682
104. Fisson S, Darasse-Jeze G, Litvinova E, et al. Continuous activation of autoreactive CD4+CD25+ regulatory T cells in the steady state. J Exp Med 2003;198:737-746
105. Walker LS, Chodos A, Eggena M, et al. Antigen-dependent proliferation of CD4+CD25+ regulatory T cells in vivo. J Exp Med 2003;198:249-258
106. Green EA, Choi Y, Flavell RA. Pancreatic lympho-node-derived CD4+CD25+ Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002;16:183-191 (Pubitemid 34211959)
107. Kryczek I, Wei S, Zou L, et al. Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007;178:6730-6733 (Pubitemid 46847396)
108. Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-350 (Pubitemid 46745409)
109. Kryczek I, Liu R, Banerjee M, et al. Th17 cells in ovarian cancer patients. Present at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer, 31 October-2 November 2008, San Diego, USA
110. Laurence A, O'Shea JJ. TH-17 differentiation: of mice and men. Nat Immunol 2007;8:903-905
111. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-949 (Pubitemid 47300008)
112. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-957 (Pubitemid 47300009)
113. Liu H, Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 2008;180:7948-7957
114. Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007;26:371-381 (Pubitemid 46413906)
115. Kryczek I, Wei S, Vatan L, et al. Opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool: IL-1 subverts IL-2-mediated suppression. J Immunol 2006;179:1423-1426
116. Kryczek I, Wei S, Zou L, et al. Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007;178:6730-6733 (Pubitemid 46847396)
117. Radhakrishnan S, Cabrera R, Schenk EL, et al. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol 2008;181:3137-3147
118. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849-1861 (Pubitemid 47240944)
119. Evans HG, Suddason T, Jackson I, et al. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci USA 2007;104:17034-17039 (Pubitemid 350210986)
120. Stummvoll GH, DiPaolo RJ, Huter EN, et al. Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol 2008;181:1908-1916
121. Chauhan SK, El Anaan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to treg suppression. J Immunol 2009;182:1247-1252